Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of M2951 in SLE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible male and female participants, aged 18 to 75 years~* Must have diagnosis of SLE with either the Systemic Lupus International Collaborating Clinics (SLICC) criteria for SLE, or at least four of the 11 American College of Rheumatology (ACR) classification criteria for SLE, of at least six months duration prior to Screening~* SLEDAI-2K total score greater than or equal to (\>=) 6 (including clinical SLEDAI greater than or equal to (\>=) 4) at Screening Visit~* And be positive for anti-double-stranded Deoxyribonucleic Acid (DNA) and/or anti-nuclear antibody (ANA greater than or equal to (\>=) 1:80) and/or anti-Smith (anti-Sm) antibody at the time of Screening~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Participants are not eligible for this study if they have active, clinically significant interstitial lung disease or pulmonary arterial hypertension~* Proteinuria (urine protein to creatinine ratio \[UPCR\] \> 4 mg/mg)~* Acutely worsened renal function~* Central nervous system SLE~* Or within two weeks prior to Screening or during Screening: use of oral corticosteroids greater than (\>) 30 mg daily prednisone equivalent~* Use of injectable corticosteroids, or change in dose of corticosteroids.~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Double-Blind Placebo-Controlled (DBPC) Period: Placebo (Type: PLACEBO_COMPARATOR): None
- DBPC Period: M2951 25 mg QD (Type: EXPERIMENTAL): None
- DBPC Period: M2951 75 mg QD (Type: EXPERIMENTAL): None
- DBPC Period: M2951 50 mg BID (Type: EXPERIMENTAL): None
- Long-Term Extension (LTE) Period: Placebo/ M2951 50 mg BID (Type: EXPERIMENTAL): None
- LTE Period: M2951 25 mg QD/ M2951 50 mg BID (Type: EXPERIMENTAL): None
- LTE Period: M2951 75 mg QD/ M2951 50 mg BID (Type: EXPERIMENTAL): None
- LTE Period: M2951 50 mg BID/ M2951 50 mg BID (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).